Inside pharma’s cleanest utility: ozone, UV — and 80°C loops — keep microbes at bay

In pharmaceutical manufacturing, purified water (PW) and water for injection (WFI) are held to exacting microbial limits—United States Pharmacopeia (USP) <1231> action levels of ~100 CFU/mL for PW and 10 CFU/100 mL for WFI (CFU: colony‑forming unit) (test.usp.org). Farmakope Indonesia aligns with USP/EP controls, and the operating reality is unforgiving: regulators and auditors scrutinize how plants prevent growth and how fast they sanitize when numbers drift.

The systems that stay in compliance combine prevention (think hot loops or a biocidal residual) with periodic disinfection. Design missteps are costly; one FDA Warning Letter trope is the overlooked dead leg or cool spot where biofilm takes hold. The operational answer is a blend of sanitary engineering, recirculation velocity, and proven sanitization technologies.

Purified Water loops: ozone and UV sanitization

PW loops typically run ambient or chilled and often include reverse osmosis (RO), deionization (DI), and ultrafiltration (UF). In practice, that can mean a RO stage, sometimes with upstream pretreatment via ultrafiltration, and ion‑exchange DI (e.g., ion exchange systems) before storage and distribution. UV‑C (ultraviolet‑C) and ozone (O₃) then shoulder the microbial control that high heat cannot—especially upstream of membranes.

Ozone (O₃) sanitization. Ozone is a powerful oxidant that rapidly destroys microorganisms and penetrates biofilm. Applying ~2 ppm for 30 minutes has been shown to achieve ~99.9999% reduction (a ~6‑log kill) (durpro.com). In daily operation, even a low residual (<50 ppb) circulating in storage inhibits regrowth; as little as 20 ppb maintained in a PW tank prevents biofilm and planktonic growth (durpro.com). Many facilities program short automated ozone flushes—e.g., 15–30 minutes daily at elevated O₃ generation—which “effectively kill bacteria, penetrate biofilm and oxidize organic species” (durpro.com).

The critical performance levers are ozone dose (mg/L) and contact time: 2 mg/L·30 min yields nearly 6‑log reduction (durpro.com), while continuous ~20 ppb suppresses re‑growth (durpro.com). Modern practice increasingly favors ozone; ISPE’s updated Ozone Sanitization Guide (2024) details design and validation and reflects that adoption (guidance-docs.ispe.org). Advantages include no chemical residues, on‑site generation, and broad efficacy. Considerations are material compatibility (ozone‑resistant 316L, PTFE, etc. durpro.com) and ensuring residual O₃ is destroyed or vented (UV or a catalyst) before point‑of‑use to meet pharmacopeial limits. Systems need oxygen feed or electrolytic generation and power; typical energy use is on the order of 0.1–0.3 kWh per kg of O₃, while eliminating liquid biocide handling. Following an ozone flush, UV lamps are turned off until ozone is scavenged by a catalyst or KI‑based destruct unit.

Ultraviolet (UV) disinfection. UV‑C at ~254 nm damages microbial DNA and is widely deployed in PW loops as a non‑chemical sanitizer. Units are often installed upstream of RO (to reduce membrane fouling) and post‑ozone to eliminate dissolved O₃ and catch survivors (durpro.com; gmpua.com). Typical lamps deliver ~30–40 mJ/cm², sufficient for >3‑log kill of common bacteria, and “add no substances” to water (durpro.com). The tradeoff: UV has no residual and depends on well‑sized intensity vs. flow, continuous movement, and lamp upkeep (typical life ~9,000–12,000 hours). For systems that use UV ahead of reverse osmosis, a dedicated RO train—such as a brackish water RO system—is a common platform. For post‑ozone polishing, purpose‑built ultraviolet units are standard at tank outlets or in the loop.

Other sanitization measures for PW (e.g., hydrogen peroxide or peracetic acid) are typically reserved for shutdown and are labor‑intensive. By contrast, ozone/UV enable in‑process sanitization with minimal downtime. Facilities adopting these two report bioburden consistently at target levels (often single‑digit CFU/mL). In one case study, switching to daily ozone sanitization stabilized tank microbial counts near zero (durpro.com).

Water for Injection loops: continuous hot distribution

WFI is held to even tighter control—action level 10 CFU/100 mL (test.usp.org)—and distribution is kept hot for thermal biocidal action. WHO, PIC/S, and USP guidance point to recirculation at ≈70–80 °C (pharmaguideline.com; pharmaguideline.com), noting systems “maintained at 70–80 °C are generally less susceptible to microbiological contamination” (pharmaguideline.com). In practice, loops often run 80–85 °C so that even with 10–15 °C loss in piping the water remains sanitizing (ask.pharmaguideline.com; ask.pharmaguideline.com). One expert notes 80 °C is “well hot enough to kill the most heat‑resistant biofilm organisms” in a water loop (ask.pharmaguideline.com).

Supporting hardware is steam‑traced or electrically heated with optimized insulation; pumps, valves, and sensors must tolerate sustained temperatures, with 316L stainless steel the typical wetted material—exemplified by pharmaceutical‑grade 316L housings such as stainless steel cartridge housings. To augment the constant thermal barrier, many sites run periodic CIP/SIP (clean‑/steam‑in‑place) cycles at ≥121 °C, aligning with WHO guidance to “sanitize or sterilize the system periodically using superheated hot water or clean steam” (pharmaguideline.com). Properly validated, WFI points of use typically culture barely above zero bacteria between cycles.

Ozone or UV in WFI loops is not practical: ozone decomposes rapidly at high temperature and can degrade materials (“the thermal stability of ozone at these temperatures is too low,” and ozonation is not recommended in hot WFI loops), and UV is seldom used on hot loops because surface irradiation there is ineffective and impractical (gmpua.com). The hot‑water barrier is the control—a “self‑sanitising” regime where mere recirculation is the main defense (gmpua.com). Plants track loop temperature closely (often >80 °C continuously); any drop below spec typically triggers immediate cleaning or shutdown.

Sanitary, dead‑leg‑free piping and equipment

Design is as important as biocides. Closed‑loop recirculation at turbulent velocities reduces biofilm formation; stagnation in dead‑end systems “often results in high bacterial counts,” leaving “flushing or repeated sanitization” as the only alternatives to recirculation (pharmtech.com). Longstanding practice targets ~3–5 ft/s (≈1–1.5 m/s) to ensure turbulence; more recently, some regulators accept any turbulent flow (Reynolds number >~2,300) (pharmtech.com; gmpua.com). One pasteurizer study found flows above ~2.5 m/s kept wall biofilms near zero compared to laminar conditions.

Dead legs—any line not swept by the loop—seed biofilm and must be minimized. Industry consensus, backed by WHO training streams, holds that a dead leg should not exceed about twice the pipe diameter (slideplayer.com). In practice, many specifications call for 2–6D maximum, with shorter better (pharmtech.com). “Zero dead‑leg” diaphragm valves and instrument tees that purge under flow are preferred; all drains and vents are air‑gapped or cascade‑drained to prevent backflow contamination.

Hygienic construction—electropolished 316L stainless steel (surface roughness Ra ≈0.4 μm or better), orbital welds, sanitary tri‑clamp fittings, and self‑draining points‑of‑use—further denies crevices where bacteria colonize. Plants that re‑piped legacy lines (removing small dead legs) have seen bioburden excursions disappear: one system with prior 4‑log CFU spikes dropped to single‑digit CFU after branch shortening and hygienic valves. Auditors frequently cite discovered dead legs as high‑risk deficiencies, reflecting contamination incidents.

Performance, monitoring, and regional practice

With these controls, robust PW loops using ozone/UV hold plate counts to <5–10 CFU/mL at outlets, and WFI loops deliver water measuring <0.01 CFU/mL (as per limits) over thousands of liters. Monitoring tracks total bacteria and biofilm ATP; statistical process control (SPC) watches average CFU, OOS excursion rates, and maintenance downtimes.

Trends favor non‑chemical in‑line sanitization (ozone/UV) for PW, a shift underscored by the 2024 ISPE guide (guidance-docs.ispe.org). Hot‑loop WFI remains the gold standard, supported by USP and WHO (pharmaguideline.com). Energy costs for hot loops are nontrivial but accepted as the price of sterility. In Indonesia, BPOM‑enforced GMP mirrors these practices; Indonesian GMP for sterile products demands validated, sanitary water systems with monitoring. Local regulations may not spell out ozone/UV explicitly, but Indonesian plants generally follow international norms (Farmakope VI/VII, WHO, PIC/S).

Sources: Authoritative guidelines and industry studies on pharmaceutical water systems (WHO, USP), plus technical reviews and practitioner resources (guidance-docs.ispe.org) (test.usp.org) (durpro.com) (durpro.com) (gmpua.com) (pharmtech.com) (pharmtech.com). These sources provide the basis for the recommendations above.